Avoro Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Avoro Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-400,000	Closed	-$87.6M	–	46
2020 Q3	$87.6M	Sell	400,000 -66,667	-14%	-$16.3M	1.24%	17
2020 Q2	$133M	Hold	466,667	–	–	2.62%	13
2020 Q1	$134M	Buy	466,667 +73,334	+19%	+$20.2M	4.54%	8
2019 Q4	$113M	Sell	393,333 -10,000	-2%	-$2.17M	3.32%	11
2019 Q3	$58.2M	Buy	+403,333	New	+$54.7M	2.43%	16
2018 Q2	–	Sell	-37,377	Closed	-$7.52M	–	52
2018 Q1	$7.52M	Buy	+37,377	New	+$7.45M	0.36%	34

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Avoro Capital Advisors's KPTI Position: Q4 2020 in Review

Avoro Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2020, closing a stake of 400,000 shares — an estimated $87.6M sold.

Avoro Capital Advisors first reported a position in KPTI in Q1 2018 and held it in 6 quarters. The position peaked at $134M in Q1 2020. 168 funds tracked by Wall St. Rank hold KPTI as of Q4 2020.

Avoro Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2020 after selling out during the quarter.
Avoro Capital Advisors sold 400,000 Karyopharm Therapeutics shares in Q4 2020, an estimated $87.6M.
Avoro Capital Advisors first reported a position in Karyopharm Therapeutics in Q1 2018 and held it in 6 quarters.
Avoro Capital Advisors's Karyopharm Therapeutics position peaked at $134M in Q1 2020.
168 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2020.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.